Upadacitinib Treats Moderate-to-Severe Atopic Dermatitis
Two replicate double-blind, randomized, placebo-controlled trials show short-term efficacy for upadacitinib in adolescents and adults
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.